Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
J Parkinsons Dis ; 2024 May 02.
Article in English | MEDLINE | ID: mdl-38701160

ABSTRACT

Background: Video-oculography constitutes a highly-sensitive method of characterizing ocular movements, which could detect subtle premotor changes and contribute to the early diagnosis of Parkinson's disease (PD). Objective: To investigate potential oculomotor differences between idiopathic PD (iPD) and PD associated with the G2019S variant of LRRK2 (L2PD), as well as to evaluate oculomotor function in asymptomatic carriers of the G2019S variant of LRRK2. Methods: The study enrolled 129 subjects: 30 PD (16 iPD, 14 L2PD), 23 asymptomatic carriers, 13 non-carrier relatives of L2PD patients, and 63 unrelated HCs. The video-oculographic evaluation included fixation, prosaccade, antisaccade, and memory saccade tests. Results: We did not find significant differences between iPD and L2PD. Compared to controls, PD patients displayed widespread oculomotor deficits including larger microsaccades, hypometric vertical prosaccades, increased latencies in all tests, and lower percentages of successful antisaccades and memory saccades. Non-carrier relatives showed oculomotor changes with parkinsonian features, such as fixation instability and hypometric vertical saccades. Asymptomatic carriers shared multiple similarities with PD, including signs of unstable fixation and hypometric vertical prosaccades; however, they were able to reach percentages of successful antisaccade and memory saccades similar to controls, although at the expense of longer latencies. Classification accuracy of significant oculomotor parameters to differentiate asymptomatic carriers from HCs ranged from 0.68 to 0.74, with BCEA, a marker of global fixation instability, being the parameter with the greatest classification accuracy. Conclusions: iPD and LRRK2-G2019S PD patients do not seem to display a differential oculomotor profile. Several oculomotor changes in asymptomatic carriers of LRRK2 mutations could be considered premotor biomarkers.

2.
Cephalalgia ; 44(4): 3331024241246242, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38573744

Subject(s)
Cough , Humans
3.
J Headache Pain ; 25(1): 69, 2024 Apr 29.
Article in English | MEDLINE | ID: mdl-38684990

ABSTRACT

BACKGROUND: Calcitonin gene-related peptide (CGRP) is the most promising candidate to become the first migraine biomarker. However, literature shows clashing results and suggests a methodological source for such discrepancies. We aimed to investigate some of these methodological factors to evaluate the actual role of CGRP as biomarker. METHODS: Previous to the experimental part, we performed a literature review of articles measuring CGRP in migraine patients. Using our 399 bio-bank sera samples, we performed a series of experiments to test the validity of different ELISA kits employed, time of sample processing, long-term storage, sampling in rest or after moderate exercise. Analysis of in-house data was performed to analyse average levels of the peptide and the effect of sex and age. RESULTS: Literature review shows the high variability in terms of study design, determination methods, results and conclusions obtained by studies including CGRP determinations in migraine patients. CGRP measurements depends on the method and specific kit employed, also on the isoform detected, showing completely different ranges of concentrations. Alpha-CGRP and beta-CGRP had median with IQR levels of 37.5 (28.2-54.4) and 4.6 (2.4-6.4)pg/mL, respectively. CGRP content is preserved in serum within the 24 first hours when samples are stored at 4°C after clotting and immediate centrifugation. Storages at -80°C of more than 6 months result in a decrease in CGRP levels. Moderate exercise prior to blood extraction does not modulate the concentration of the peptide. Age positively correlates with beta-CGRP content and men have higher alpha-CGRP levels than women. CONCLUSIONS: We present valuable information for CGRP measurements in serum. ELISA kit suitability should be tested prior to the experiments. Alpha and beta-CGRP levels should be analysed separately as they can show different behaviours even within the same condition. Samples can be processed in a 24-h window if they have been kept in 4°C and should not be stored for more than 6 months at -80°C before assayed. Patients do not need to rest before the blood extraction unless they have performed a high-endurance exercise. For comparative studies, sex and age should be accounted for as these parameters can impact CGRP concentrations.


Subject(s)
Biomarkers , Calcitonin Gene-Related Peptide , Migraine Disorders , Humans , Migraine Disorders/blood , Migraine Disorders/diagnosis , Calcitonin Gene-Related Peptide/blood , Biomarkers/blood , Male , Female , Adult , Middle Aged , Enzyme-Linked Immunosorbent Assay
4.
Cephalalgia ; 44(3): 3331024241233979, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38427755

ABSTRACT

BACKGROUND: Some studies have suggested an association between migraine and inflammatory bowel disease. We determined migraine prevalence in a cohort of patients with inflammatory bowel disease. METHODS: Patients with inflammatory bowel disease aged 18-65 years were interviewed using an ad hoc headache questionnaire. Those who admitted a history of headache in the last year answered the three questions of the ID-Migraine questionnaire. Those who answered "yes" to the three of them were classified as "definite" and those who answered "yes" to two were classified as "probable" migraine. RESULTS: We interviewed 283 patients with inflammatory bowel disease. Of these, 176 (62.2%) had headache. Fifty-nine (20.8%; 95% CI 16.3-26.0%) met migraine criteria either definite (n = 33; 11.7%; 95% CI 8.2-16.0%) or probable (n = 26; 9.2%; 95% CI 6.1-13.2). When divided by gender, 12 men (9.6%; 95% CI 5.1-16.2%) and 47 women (29.8%; 95% CI 22.8-37.5%) met migraine criteria. The prevalence of migraine was increased in inflammatory bowel disease patients from the current cohort (20.8%) versus that reported for our general population for the same age group (12.6%; p < 0.0001). These differences remained significant in female inflammatory bowel disease patients (29.8% versus 17.2% in our general population; p < 0.0001), but not in males (9.6% in inflammatory bowel disease vs 8.0%; p = 0.30). Seventeen patients with inflammatory bowel disease (6.0%; 95% CI 3.54-9.44%) fulfilled chronic migraine criteria. There were no differences in migraine prevalence by inflammatory bowel disease subtypes. CONCLUSION: Migraine prevalence, including chronic migraine, seems to be increased in patients with inflammatory bowel disease. The fact that this association was stronger for women suggests an influence of sex-related factors.


Subject(s)
Inflammatory Bowel Diseases , Migraine Disorders , Male , Humans , Female , Cross-Sectional Studies , Prevalence , Migraine Disorders/epidemiology , Headache/epidemiology , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/epidemiology
5.
Ann Neurol ; 94(2): 285-294, 2023 08.
Article in English | MEDLINE | ID: mdl-37038806

ABSTRACT

OBJECTIVE: The objective of this study was to analyze the evolution of alpha and beta-CGRP circulating levels throughout CGRP monoclonal antibodies (mAbs) treatment in patients with chronic migraine (CM). METHODS: We recruited patients with CM beginning mAbs along with sex and age paired healthy controls (HCs). Blood was extracted before, 2 weeks (M0.5) and 3 months (M3) after the first dose of mAbs, always in free-migraine periods, and once for HCs. Alpha and beta-CGRP serum levels were measured using enzyme-linked immunosorbent assays (ELISAs) specific for each isoform. RESULTS: Baseline alpha-CGRP levels were significantly elevated in 103 patients with CM (median = 50.3, 95% confidence interval [CI] = 40.5-57.0 pg/ml) compared to 78 HCs (median = 37.5, 95% CI = 33.9-45.0 pg/ml; 95% CI of differences = 2.85-17.08 pg/ml) and significantly decreased (n = 96) over the course of mAb treatment (M0.5: median = 40.4, 95% CI = 35.6-48.2 pg/ml; and M3: median = 40.9, 95% CI = 36.3-45.9 pg/ml). Absolute decrease of alpha-CGRP throughout the treatment positively correlated with the decrease in MMDs. Negative modulation of alpha-CGRP significantly associated with positive scores at the Patient Global Impression of Change scale and with analgesic overuse reversal. Beta-CGRP did not differ at baseline between patients with CM (median = 4.2, 95% CI = 3.0-4.8 pg/ml) and HCs (median = 4.4, 95% CI = 3.4-5.6 pg/ml; -1.09 to 0.60) nor was modulated by mAb treatment (n = 96; M0.5: median = 4.5, 95% CI = 3.5-5.2 pg/ml; and M3: median = 4.6, 95% CI = 3.7-5.2 pg/ml). INTERPRETATION: Treatment with mAbs, regardless of its target, is able to progressively normalize basally increased alpha-CGRP levels in CM and this effect correlates with efficacy measures, which supports a role of this neuropeptide as the first CM biomarker. ANN NEUROL 2023;94:285-294.


Subject(s)
Calcitonin Gene-Related Peptide , Migraine Disorders , Humans , Antibodies, Monoclonal/therapeutic use , Biomarkers
6.
BMC Neurol ; 23(1): 109, 2023 Mar 17.
Article in English | MEDLINE | ID: mdl-36932352

ABSTRACT

BACKGROUND: Headache is among the most frequent symptoms of acute COVID-19 infection. Its mechanisms remain obscure, but due to its migraine-like characteristics, the activation of the trigeminal system could account for its underlying pathophysiology. METHODS: Our aim was to compare the serum levels of CGRP, as a theoretical marker of trigemino-vascular activation, in 25 COVID-19 inpatients with lung involvement experiencing headache, against 15 COVID-19 inpatients without headache and with those of 25 matched healthy controls with no headache history. RESULTS: Morning serum alpha-CGRP levels, as measured by ELISA (Abbexa, UK), were increased in COVID-19 patients with headache (55.2±34.3 pg/mL) vs. controls (33.9±14.0 pg/mL) (p < 0.01). Alpha-CGRP levels in COVID-19 patients without headache were also significantly increased (43.3 ± 12.8 pg/mL; p = 0.05) versus healthy controls, but were numerically lower (-28.2%; p = 0.36) as compared to COVID-19 patients with headache. CONCLUSION: CGRP levels are increased in COVID-19 patients experiencing headache in the acute phase of this disease, which could explain why headache frequently occurs in COVID-19 and strongly supports a role for trigeminal activation in the pathophysiology of headache in this viral infection.


Subject(s)
COVID-19 , Migraine Disorders , Humans , Calcitonin Gene-Related Peptide , Headache , Inpatients
7.
Cephalalgia ; 43(3): 3331024221146989, 2023 03.
Article in English | MEDLINE | ID: mdl-36786294

ABSTRACT

BACKGROUND: Headaches associated with physical exertion include headache precipitated by coughing or other Valsalva maneuvers, headache brought on by prolonged physical exercise, sexual headaches and cardiac cephalalgia. OBJECTIVE: To review and update the clinical characteristics, etiologies, pathophysiology and management of these headaches related to exertion. METHODS: In depth review of the publications, both in PubMed and in the main textbooks, of the different headaches induced by physical exercise. RESULTS: Cough, exercise and sexual headaches can be primary or secondary; therefore, complementary studies are mandatory to rule out structural lesions. However, clinical characteristics, such as an old age and response to indomethacin for cough headache or being a young male and response to beta-blockers for exercise and sexual headaches, plus a normal examination are suggestive of a primary etiology. Etiology for secondary varieties, as posterior fossa lesions for cough headache or vascular malformations for exercise and sexual headaches, are also different. Finally, headache as a distant manifestation of myocardial ischemia, also known as "cardiac cephalalgia", appears at exertion in around two-thirds of cases and typically lasts less than 30 minutes and is relieved by nitroglycerine. CONCLUSIONS: Primary and secondary cough headache can usually be suspected based on clinical characteristics and separated from exercise and sexual headaches, which share many aspects. Cardiac cephalalgia is not necessarily an exertional headache and should be considered in adult patients with short lasting headaches and patent vascular risk factors.


Subject(s)
Headache Disorders, Primary , Physical Exertion , Adult , Humans , Male , Headache/etiology , Headache/therapy , Headache/diagnosis , Sexual Behavior/physiology , Exercise , Headache Disorders, Primary/diagnosis , Cough
8.
Arch Med Res ; 54(1): 56-63, 2023 01.
Article in English | MEDLINE | ID: mdl-36588002

ABSTRACT

BACKGROUND: Vasoactive peptides play an important role in a wide range of physiological and pathological conditions. Due to its known functions, the calcitonin gene-related peptide (CGRP) has been suggested as a possible modulator of the hyperimmune response in COVID-19 and thus, blocking its action may lessen the pulmonary effects of COVID-19. AIM OF THE STUDY: To compare the circulating levels of CGRPα and CGRPß in healthy controls compared to hospitalized COVID-19 patients. The study also analyzed how different comorbidities and treatments may affect these concentrations in cases of COVID-19 infection with pulmonary involvement METHODS: Serum samples were collected from the antecubital vein of 51 control subjects (mean age = 55 ± 14 years; range = 26-77; 56.9% female) and 52 patients hospitalized with COVID-19 infection (mean age = 55 ± 13; range = 23-77; 55.8% female) from December 2020 to May 2021. Enzyme-linked immunosorbent assays (ELISAs) were used for CGRPα (Abbexa, UK) and CGRPß (CUSABIO, China) measurements. Comorbidities, symptoms, and treatments of infection were listed. RESULTS: The results showed that the serum levels of both isoforms of CGRP were significantly higher in patients with COVID-19 (α: 57.9 ± 35.8 pg/mL; ß: 6.1 ± 2.6 pg/mL) compared to controls (α: 41.8 ± 25.4 pg/mL; ß: 4.5 ± 2.4 pg/mL) (p <0.01). Also, the presence of arterial hypertension (HT), obesity, or corticosteroid treatment significantly alter the serum concentration of CGRPα in the subgroups compared to controls. CONCLUSION: The elevated serum CGRP levels found in our COVID-19 group compared to controls may suggest that CGRP plays a role in the pathophysiology of the disease, more specifically, in the cytokine storm and in the pulmonary involvement. Future studies should focus on the source of this CGRP elevation.


Subject(s)
COVID-19 , Hypertension , Adult , Aged , Female , Humans , Male , Middle Aged , Calcitonin Gene-Related Peptide/physiology , China , Inpatients , Young Adult
9.
J Headache Pain ; 23(1): 85, 2022 Jul 21.
Article in English | MEDLINE | ID: mdl-35864440

ABSTRACT

BACKGROUND AND AIM: Headache attributed to intracranial endovascular procedures is described in the ICHD-3. Our aim was to study the frequency and characteristics of headache specifically related to thrombectomy in patients with ischemic stroke. METHODS: Prospective evaluation of clinical features of headache after thrombectomy using an ad hoc questionnaire. RESULTS: One hundred seventeen patients were included (52.1% females). Most had an anterior circulation artery occlusion (91.5%). 93 (79.5%) received general anaesthesia. 111 (94.9%) required stent retriever, 21 (24.4%) angioplasty and 19 (16.2%) aspiration thrombectomy. 31 (26.5%; 95% CI 18.8-35.5%) had headache related to thrombectomy, and it was associated with a history of primary headache (p = 0.004). No differences about sex, initial NIHSS score, or the type or complexity of the procedure were observed. Headache was usually moderate and oppressive, ipsilateral to the artery occlusion and usually lasted less than 48 hours. CONCLUSIONS: Almost one-third of patients with ischemic stroke who undergo endovascular thrombectomy experience headache in the first 24 hours, occurring more frequently in patients who had a previous history of headaches regardless of the procedure complexity.


Subject(s)
Brain Ischemia , Endovascular Procedures , Ischemic Stroke , Stroke , Brain Ischemia/complications , Brain Ischemia/surgery , Endovascular Procedures/methods , Female , Headache/etiology , Headache/surgery , Humans , Ischemic Stroke/complications , Ischemic Stroke/surgery , Male , Prospective Studies , Stroke/complications , Stroke/surgery , Thrombectomy/adverse effects , Treatment Outcome
12.
J Neurol Sci ; 434: 120122, 2022 Mar 15.
Article in English | MEDLINE | ID: mdl-34979370

ABSTRACT

OBJECTIVE: To assess the frequency of symptomatic structural lesions and the diagnostic yield of conventional brain MRI in cluster headache (CH). BACKGROUND: In contrast to migraine, brain MRI is recommended in patients with CH to exclude potential mimics. The prevalence of symptomatic CH is not known. METHODS: We retrospectively analysed in detail the brain MRIs of patients diagnosed as CH in 3 Neurology Services in Spain and reviewed their clinical history. Clinical diagnoses were reassessed based on the ICHD-3 criteria. RESULTS: We included 130 patients: 113 (86.9%) were male; mean age at diagnosis being 41.4 years (range 7-82). Forty-nine (37.7%) showed some abnormal MRI finding. Only in two cases potential symptomatic lesions were found: one trigeminal schwannoma and one craneopharyngioma, but both presented atypical features (facial hypoesthesia on examination and episodes of prolonged duration that had progressed to continuous refractory pain without specific pattern, respectively) and therefore did not fulfil the ICHD-3 CH criteria. The remaining abnormal MRI findings were: white matter lesions (24 patients; 18.4%), sinus inflammatory changes (13; 10.0%), small arachnoid cysts (5; 3.8%), empty sella turca (3; 2.3%), and other unspecific findings (8; 6.2%). All of them were not symptomatic based on neuroimaging characteristics, clinical course and response to treatment. CONCLUSIONS: Brain MRI in patients who meet ICHD-3 CH criteria, with no atypical clinical features, does not show any clinically-relevant findings, suggesting that these criteria are highly predictive of its primary origin and that systematic MRI is not useful for the diagnosis of typical CH.


Subject(s)
Cluster Headache , Adolescent , Adult , Aged , Aged, 80 and over , Brain/diagnostic imaging , Child , Cluster Headache/diagnostic imaging , Hospitals , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neuroimaging , Retrospective Studies , Spain/epidemiology , Young Adult
13.
Eur J Neurol ; 28(12): 4204-4208, 2021 12.
Article in English | MEDLINE | ID: mdl-34407293

ABSTRACT

BACKGROUND: Carriers of the G2019S mutation of LRRK2 provide a great opportunity to investigate the premotor stages of Parkinson's disease (PD). We have studied by serial clinical and dopamine transporter single photon emission computed tomography (DaT-SPECT) evaluations a cohort of asymptomatic carriers of the LRRK2-G2019S mutation in order to evaluate the usefulness of these tools as biomarkers. Here we report the results of the extended follow-up of this cohort at 8 years. METHODS: Seventeen participants, of the 25 available from the 4-year evaluation, completed the 8-year assessment. UPDRS-III, UPSIT test and DaT-SPECT imaging (123 I-ioflupane) were performed. We used repeated-measures linear mixed effects models to examine the changes in DaT binding over time. RESULTS: Three carriers had converted to PD at 4 years. One additional carrier converted at 8 years. PD-converters had lower striatal DaT binding at baseline than non-converters. There was a significant decline of DaT binding over time, with a mean annual rate of 3.5%, with somewhat inter-individual and intra-individual variability and comparable between PD-converters and non-converters. No carrier with DAT binding ratio above an undefined threshold between 0.5 and 0.8 developed PD symptoms. The age-adjusted UPSIT score did not change significantly over time. CONCLUSIONS: The rate of conversion to PD at 8 years in this cohort aged ~58 years at baseline was 16%. The observed decline of DaT binding over time and its association with the phenotype render DaT-SPECT a potentially useful tool for monitoring the premotor stage of the disease, although at the individual level its ability to predict phenoconversion is limited.


Subject(s)
Dopamine Plasma Membrane Transport Proteins , Tomography, Emission-Computed, Single-Photon , Aged , Dopamine Plasma Membrane Transport Proteins/genetics , Dopamine Plasma Membrane Transport Proteins/metabolism , Follow-Up Studies , Humans , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/genetics , Mutation
14.
Cephalalgia ; 41(11-12): 1272-1275, 2021 10.
Article in English | MEDLINE | ID: mdl-34082583

ABSTRACT

BACKGROUND: One of the advantages of CGRP monoclonal antibodies is their excellent safety and tolerability. However, postmarketing surveillance, is essential to detect potential rare emergent adverse events. OBJECTIVES: To report two patients who developed restless legs syndrome symptoms after treatment with CGRP antibodies. METHODS AND RESULTS: Two women with chronic refractory migraine, with no significant medical antecedents, developed typical restless legs syndrome symptoms 1.5 and 4 months after starting erenumab 140 mg, respectively. In case 1 symptoms resolved when erenumab was stopped for two months but reappeared on galcanezumab. In both patients migraine attacks had dramatically decreased and no iron deficiency was found. CONCLUSIONS: Even though caution is needed before establishing a causal relationship, these cases suggest that restless legs-like symptoms might be an emergent adverse event of CGRP antibodies, regardless of the mechanism of action. We propose that plastic changes in CGRP sensory fibers, which are very abundant in legs, induced by CGRP monoclonal antibodies could be the reason for restless legs syndrome development.


Subject(s)
Migraine Disorders , Restless Legs Syndrome , Antibodies, Monoclonal/adverse effects , Calcitonin Gene-Related Peptide , Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use , Female , Humans , Migraine Disorders/chemically induced , Migraine Disorders/drug therapy , Restless Legs Syndrome/chemically induced , Restless Legs Syndrome/diagnosis , Restless Legs Syndrome/drug therapy
15.
Rev. Fund. Educ. Méd. (Ed. impr.) ; 24(2): 77-83, Abr. 2021. graf
Article in Spanish | IBECS | ID: ibc-225202

ABSTRACT

Introducción: El examen clínico objetivo estructurado (ECOE) se aplica desde la década de los setenta en la mayoría de las escuelas de medicina del mundo. Este examen consiste en una dinámica en la que los estudiantes rotan por estaciones, dotadas de todo lo necesario para realizar un procedimiento clínico en un tiempo determinado. Objetivo: Analizar la percepción del ECOE como instrumento de evaluación para estudiantes de tercer año de Odontología de la sede de Santiago de la Universidad San Sebastián de Chile en 2018. Sujetos y métodos: Se realizó una investigación exploratoria aplicando una encuesta que mide la percepción frente a la experiencia del ECOE por los estudiantes de tercer año de la carrera de Odontología. Resultados: Los resultados indicaron que los estudiantes percibieron que el ECOE estuvo bien implementado, la mayoría pensó que mide sus habilidades y conocimientos adquiridos en años anteriores, y consideran que lo evaluado es importante para los años posteriores de su carrera. Conclusión: Los estudiantes tienen una percepción adecuada del ECOE como instrumento evaluativo; se pudo obtener información para realizar mejoras en futuras implementaciones.(AU)


Introduction: The objective structured clinical examination (OSCE) has been used since the 1970s in most medical schools worldwide. It consists of students being tested at different workstations, where they must perform a clinical procedure. Each station is equipped with everything necessary to perform a clinical procedure within a certain time. Aim: The perception of the OSCE was analyzed as an evaluation instrument for third-year students of Dentistry at the San Sebastian University, Santiago, Chile in 2018. Subjects and methods: An exploratory research was carried out applying a survey that measures the perception of the experience of the OSCE by third-year students of the Dentistry career. Results: The results indicated that the students perceived was well implemented. The majority thought that the OSCE measured their skills and knowledge acquired in previous years and that what was asked was important for the later years of their careers. It was observed that they considered the fairest evaluation of the OSCE, the most difficult -the preclinical enabling tests. It was also reported that they preferred to be evaluated more frequently with the OSCE. Conclusion: The students have an adequate perception of the ECOE as an evaluation instrument and that information could be obtained to make improvements in future implementations.(AU)


Subject(s)
Humans , Students, Dental , Education, Dental , Education, Medical/methods , Clinical Competence , Dentistry , Surveys and Questionnaires , Chile
16.
Headache ; 60(10): 2570-2572, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32491189

ABSTRACT

Many patients with chronic migraine are difficult to treat. We present a patient with chronic migraine with good response to onabotulinum toxin type A whose headaches worsened in clear temporal relationship to local treatment with glyceryl trinitrate for an anal fissure. Our case shows that the use, even at distance, of nitric oxide donors can be a precipitating factor for migraineurs and should be always inquired in chronic migraine patients. In addition, the presence of frequent headaches should always be ruled out before prescribing such medications.


Subject(s)
Botulinum Toxins, Type A/pharmacology , Fissure in Ano/drug therapy , Migraine Disorders/chemically induced , Migraine Disorders/prevention & control , Neuromuscular Agents/pharmacology , Nitric Oxide Donors/adverse effects , Nitroglycerin/adverse effects , Adult , Female , Humans , Ointments
17.
Rev cienc méd pinar río ; 10(1S)sept. 2006. ilus
Article in Spanish | CUMED | ID: cum-33090

ABSTRACT

Con el objetivo de proponer e introducir una Estrategia para la Eficiencia y Competencia Laboral en el Departamento de Secretaría General de la Facultad de Ciencias Médicas de Pinar del Río, realizamos un estudio descriptivo transversal desde septiembre del 2004 hasta julio del 2005, donde se aplicaron entrevistas, encuestas, observación directa sobre la base de los resultados del mismo, entre los que se destacan la consagración al trabajo, alternativas para dar solución a los problemas, superación de éstos, permanencia de los colaboradores en su esfera de trabajo, una activa motivación, satisfacción y un sistema de perfeccionamiento y universalización que ayude a potencializar la puesta en marcha de la Estrategia para la Eficiencia y Competencia. Se elaboró una propuesta para tales fines, la cual se está aplicando al Dpto., corroborándose algunos resultados esperados. Se concluye que la Estrategia propuesta constituye una herramienta útil para garantizar la efectividad en las definiciones de perfiles de competencia, permite ofrecer elementos sobre las distintas concepciones, beneficios y requisitos necesarios, un entendimiento para la integración de la Gestión de Recursos Humanos con los objetivos estratégicos de la institución, buscando calidad con el menor gasto de recursos posibles...(AU)


Subject(s)
Efficiency
SELECTION OF CITATIONS
SEARCH DETAIL
...